LONDON: First test results for a coronavirus vaccine being developed by the University of Oxford, in collaboration with AstraZeneca Plc, show that it produces a robust immune response in older people, the highest risk group, the Financial Times reported. Monday.
The vaccine was found to trigger protective antibodies and T cells in older age groups, the newspaper said, citing two people familiar with the finding, encouraging researchers to seek evidence that it will prevent those in the future from having a disease. serious or death. of the virus.
The findings echo data published in July that showed the vaccine elicited “robust immune responses” in a group of healthy adults aged 18 to 55, the newspaper reported, citing people aware of the results of the so-called analyzes. immunogenicity blood test.
But the FT cautioned that positive immunogenicity tests do not guarantee that the vaccine will ultimately prove safe and effective in older people.
AstraZeneca, which is developing the vaccine with researchers at the University of Oxford, is seen as a pioneer in the race to produce a vaccine to protect against Covid-19.
Details of the finding are expected to be published shortly in a clinical journal, FT said, without naming a journal.
Oxford and AstraZeneca did not immediately respond to Reuters’ request for comment.
The vaccine was found to trigger protective antibodies and T cells in older age groups, the newspaper said, citing two people familiar with the finding, encouraging researchers to seek evidence that it will prevent those in the future from having a disease. serious or death. of the virus.
The findings echo data published in July that showed the vaccine elicited “robust immune responses” in a group of healthy adults aged 18 to 55, the newspaper reported, citing people aware of the results of the so-called analyzes. immunogenicity blood test.
But the FT cautioned that positive immunogenicity tests do not guarantee that the vaccine will ultimately prove safe and effective in older people.
AstraZeneca, which is developing the vaccine with researchers at the University of Oxford, is seen as a pioneer in the race to produce a vaccine to protect against Covid-19.
Details of the finding are expected to be published shortly in a clinical journal, FT said, without naming a journal.
Oxford and AstraZeneca did not immediately respond to Reuters’ request for comment.
.
